Cannabidiol for Depression in bipolarity (CBD-BD)
This study is recruiting. It focuses on bipolarity and currently lists participation information in Canada.
Multiple locations, including Vancouver
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study is recruiting. It focuses on bipolarity and currently lists participation information in Canada.
Multiple locations, including VancouverThis study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
In BaltimoreThis study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
Multiple locations, including BelmontThis study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
In Iowa CityThis study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
In WorcesterThis study is recruiting. It focuses on bipolarity and currently lists participation information in France.
In ParisThis study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
Multiple locations, including Los AngelesThis study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
Multiple locations, including Los AngelesThis study is recruiting. It focuses on depression and currently lists participation information in China.
In HangzhouThis study is recruiting in the United Kingdom. It is testing an aripiprazole and sertraline drug combination for depression in bipolarity.
In United KingdomThis study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.
In San FranciscoThis study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
Multiple locations, including Hartford